• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dainippon Sumitomo Pharma to acquire Boston Biomedical

Dainippon Sumitomo Pharma to acquire Boston Biomedical

March 1, 2012
CenterWatch Staff

Dainippon Sumitomo Pharma (DSP) of Osaka, Japan, plans to acquire Norwood, Mass.-based Boston Biomedical (BBI).

DSP will make an upfront payment of $200 million to BBI shareholders, and will make development milestone payments of up to $540 million related to compounds BBI608 and BBI503 currently in development. It will also pay up to $1.9 billion in sales milestones.

DSP currently aims to commercialize BBI608 and BBI503 in 2015 or later. Both are small molecular oral drugs that aim to cause an antitumor effect in cancer stem cells. Although there are no successful anticancer drugs thus far, BBI and DSP believe BBI608 and BBI503 are likely to become the first anticancer drugs in the world targeting cancer stem cells. BBI608 is currently in the preparatory stage for phase III clinical trial for colorectal cancer inNorth Americaand in phase Ib and II clinical trials for various solid tumors. BBI503 is in phase I clinical trial for patients with various advanced solid tumors inNorth America.

DSP signed an exclusive license agreement with BBI in March 2011 for the rights to develop and commercialize BBI608 in Japanfor all indications of cancer. Seeing BBI's development pipeline led to DSP's decision to acquire BBI.

Acquisition of BBI is not only an acquisition of an innovative pipeline in the oncology area, it also represents obtaining an excellent drug discovery/development platform with the capabilities of BBI, enabling us to continuously create candidate compounds likely to advance into later development stages,” said Masayo Tada, president and CEO of DSP. “Subsequently we intend to establish our R&D base in the U.S. to expand our presence in cancer treatment globally. We are aiming to make the oncology area one of our future focus therapeutic areas next to the CNS area.

Once the acquisition closes in April, BBI will become a 100% owned subsidiary of DSP and continue its operation in the Boston area.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing